期刊
PEDIATRIC BLOOD & CANCER
卷 54, 期 3, 页码 350-354出版社
WILEY
DOI: 10.1002/pbc.22136
关键词
cytokines; interferon; osteosarcoma; treatment
资金
- Department of Health's NIHR Biomedical Research Centers funding scheme
Interferons, a group of cytokines with antiangiogenic, direct antitumour and immunostimulating properties, have shown significant activity against osteosarcoma in vitro and in xenograft models. They have also been used in osteosarcoma clinical trials as a single adjuvant to Surgery, with an apparent increase in relapse-free Survival. In the ongoing EURAMOS 1 clinical trial, interferon alpha-2b is evaluated as an adjuvant treatment in osteosarcoma. This article reviews the rationale for the use of interferon in cancer with special reference to the treatment of osteosarcoma, including all published data of clinical efficacy in this disease. Pediatr Blood Cancer 2010;54:350-354. (C) 2009 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据